Endocare Reports Progress on Development of New Technologies for Prostate Cryoablation at Investor Conference

Three Separate Research Efforts to Address Lower-Risk Patient Population;

Encouraging Data On Post-Operative Potency Rates



Apr 12, 2001, 01:00 ET from Endocare, Inc.

    IRVINE, Calif., April 12 /PRNewswire/ -- Endocare, Inc. (Nasdaq:   ENDO), a
 developer of innovative temperature-based treatments for prostate cancer and
 prostate obstruction, yesterday reported progress made to develop a nerve-
 sparing cryoablation technology that addresses lower-risk prostate patients at
 the 30th Annual Robertson-Humphrey Institutional Conference in Atlanta.  Post-
 operative impotency is a concern for the vast majority of prostate cancer
 patients and a nerve-sparing cryoablation procedure could largely eliminate
 this side-effect for appropriate patient groups.
     Endocare Chairman and Chief Executive Officer Paul Mikus indicated during
 his presentation to conference attendees that the Company has launched an
 aggressive program to determine the most effective manner of attaining higher
 rates of post-operative potency for those who undergo prostate cryoablation.
 The Company has targeted an 80 percent post-operative potency rate in patients
 with lower-risk prostate cancer.  The current research efforts show
 encouraging progress towards achieving these objectives.
     In his presentation, Mikus said that the revenue growth seen in recent
 quarters is an indication that the Urology community is beginning to readily
 embrace Cryoablation as an important, if not first, option for prostate cancer
 patients.  He indicated that successful development of a nerve-sparing
 cryoablation technology is an important step in reaching the portion of the
 market that is younger and whose cancer is in the early stages.
     Mikus stated, "These potential advances would only enhance the current
 advantages of the procedure and further fulfill its potential as a curative,
 repeatable and minimally invasive answer for prostate cancer patients."
     One effort, involving patients with low-grade disease, involved treatment
 with a nerve-sparing freezing technique.  Initial data from this small number
 of patients, who have been followed up from two to five years, has shown that
 significant potency rates were achieved without compromising cancer control.
 The Company plans to launch a broader-scale clinical investigation by the end
 of the year.
     A second program involves the use of injecting a cryoprotective agent into
 the nerve bundle in an effort to retard damage to the area during the
 procedure.  Initial animal experiments showed that at least one of the agents
 showed substantial promise toward this goal and further pre-clinical work,
 using a more refined protocol are currently under consideration.
     The third program discussed involves the placement of additional
 protective mechanisms near the nerve bundles during the procedure.  These
 initial studies demonstrated that it is possible to protect the nerve bundles
 from freezing while destroying the diseased prostate tissue.  The Company
 anticipates further preliminary and clinical work to focus on this technique.
 
     About Endocare
     Endocare, Inc. -- www.endocare.com -- is a vertically-integrated medical
 device company that develops, manufactures and markets cryosurgical and stent
 technologies for applications in oncology and urology.  The Company has
 initially concentrated on developing devices for the treatment of the two most
 common diseases of the prostate, prostate cancer and benign prostate
 hyperplasia.  The Company is also developing cryosurgical technologies for
 treating tumors in other organs, including the kidney, breast and liver.
 
     This release contains forward-looking statements.  These statements are
 subject to risk and uncertainties including, but not limited to, those
 discussed in the Company's most recent Annual Report on Form 10-K, Quarterly
 Report on Form 10-Q and other filings with the Securities and Exchange
 Commission.  Such risk factors include, but are not limited to, limited
 operating history of the Company with a history of losses; fluctuations in the
 Company's order levels; uncertainty regarding market acceptance of the
 Company's new products; uncertainty of product development and the associated
 risks related to clinical trials; the rapid pace of technological change in
 the Company's industry; the Company's limited sales, marketing and
 manufacturing experience; the ability to secure and protect intellectual
 property rights relating to the Company's technology and the ability to
 convince health care professionals and third party payers of the medical and
 economic benefits of the Company's products.  The actual results that the
 Company achieves may differ materially from any forward-looking statements due
 to such risks and uncertainties.  We undertake no obligation to revise or
 update publicly any forward-looking statements for any reason.
 
     For further information please contact Matt Clawson, matt@allencaron.com,
 or Media, Len Hall, Len@allencaron.com, both of Allen & Caron, Inc., 949-474-
 4300, for Endocare, Inc.; or Paul Mikus, President and CEO, or William Hughes,
 Senior Vice President and CFO, both of Endocare, Inc., 949-595-4770.
 
 

SOURCE Endocare, Inc.
    IRVINE, Calif., April 12 /PRNewswire/ -- Endocare, Inc. (Nasdaq:   ENDO), a
 developer of innovative temperature-based treatments for prostate cancer and
 prostate obstruction, yesterday reported progress made to develop a nerve-
 sparing cryoablation technology that addresses lower-risk prostate patients at
 the 30th Annual Robertson-Humphrey Institutional Conference in Atlanta.  Post-
 operative impotency is a concern for the vast majority of prostate cancer
 patients and a nerve-sparing cryoablation procedure could largely eliminate
 this side-effect for appropriate patient groups.
     Endocare Chairman and Chief Executive Officer Paul Mikus indicated during
 his presentation to conference attendees that the Company has launched an
 aggressive program to determine the most effective manner of attaining higher
 rates of post-operative potency for those who undergo prostate cryoablation.
 The Company has targeted an 80 percent post-operative potency rate in patients
 with lower-risk prostate cancer.  The current research efforts show
 encouraging progress towards achieving these objectives.
     In his presentation, Mikus said that the revenue growth seen in recent
 quarters is an indication that the Urology community is beginning to readily
 embrace Cryoablation as an important, if not first, option for prostate cancer
 patients.  He indicated that successful development of a nerve-sparing
 cryoablation technology is an important step in reaching the portion of the
 market that is younger and whose cancer is in the early stages.
     Mikus stated, "These potential advances would only enhance the current
 advantages of the procedure and further fulfill its potential as a curative,
 repeatable and minimally invasive answer for prostate cancer patients."
     One effort, involving patients with low-grade disease, involved treatment
 with a nerve-sparing freezing technique.  Initial data from this small number
 of patients, who have been followed up from two to five years, has shown that
 significant potency rates were achieved without compromising cancer control.
 The Company plans to launch a broader-scale clinical investigation by the end
 of the year.
     A second program involves the use of injecting a cryoprotective agent into
 the nerve bundle in an effort to retard damage to the area during the
 procedure.  Initial animal experiments showed that at least one of the agents
 showed substantial promise toward this goal and further pre-clinical work,
 using a more refined protocol are currently under consideration.
     The third program discussed involves the placement of additional
 protective mechanisms near the nerve bundles during the procedure.  These
 initial studies demonstrated that it is possible to protect the nerve bundles
 from freezing while destroying the diseased prostate tissue.  The Company
 anticipates further preliminary and clinical work to focus on this technique.
 
     About Endocare
     Endocare, Inc. -- www.endocare.com -- is a vertically-integrated medical
 device company that develops, manufactures and markets cryosurgical and stent
 technologies for applications in oncology and urology.  The Company has
 initially concentrated on developing devices for the treatment of the two most
 common diseases of the prostate, prostate cancer and benign prostate
 hyperplasia.  The Company is also developing cryosurgical technologies for
 treating tumors in other organs, including the kidney, breast and liver.
 
     This release contains forward-looking statements.  These statements are
 subject to risk and uncertainties including, but not limited to, those
 discussed in the Company's most recent Annual Report on Form 10-K, Quarterly
 Report on Form 10-Q and other filings with the Securities and Exchange
 Commission.  Such risk factors include, but are not limited to, limited
 operating history of the Company with a history of losses; fluctuations in the
 Company's order levels; uncertainty regarding market acceptance of the
 Company's new products; uncertainty of product development and the associated
 risks related to clinical trials; the rapid pace of technological change in
 the Company's industry; the Company's limited sales, marketing and
 manufacturing experience; the ability to secure and protect intellectual
 property rights relating to the Company's technology and the ability to
 convince health care professionals and third party payers of the medical and
 economic benefits of the Company's products.  The actual results that the
 Company achieves may differ materially from any forward-looking statements due
 to such risks and uncertainties.  We undertake no obligation to revise or
 update publicly any forward-looking statements for any reason.
 
     For further information please contact Matt Clawson, matt@allencaron.com,
 or Media, Len Hall, Len@allencaron.com, both of Allen & Caron, Inc., 949-474-
 4300, for Endocare, Inc.; or Paul Mikus, President and CEO, or William Hughes,
 Senior Vice President and CFO, both of Endocare, Inc., 949-595-4770.
 
 SOURCE  Endocare, Inc.